Regulation 3 Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002

In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of Regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—

(a)

after “Tenocyclidine” insert—

“(6aR,9R-4-acetyl-N, N-diethyl-7-methyl-4, 6, 6a, 7, 8, 9-hexahydroindolo[4, 3-fg]quinoline-9-carboxamide (ALD-52”;

(b)

after “4-Bromo-2,5-dimethoxy-a-methylphenethylamine” insert—

“3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)

(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)

(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)

(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)”

(c)

after “2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol” insert—

“2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg]quinolin-9-yl}methanone (LSZ)”.